News
-
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Communiqué de presse : Qfitlia et Cablivi de Sanofi approuvés en Chine, élargissant la prise en charge des maladies rares
Sanofi voit Qfitlia et Cablivi approuvés en Chine pour traiter les maladies rares, marquant une avancée significative avec des approbations récentes dans le domaine de l'hématologie -
COMMUNIQUÉ DE PRESSE
Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases
Sanofi's Qfitlia and Cablivi have been approved in China by the National Medical Products Administration, expanding care for rare diseases in the country. Qfitlia offers protection for hemophilia with as few as six injections a year, while Cablivi targets a rare life-threatening blood clotting disorder -
COMMUNIQUÉ DE PRESSE
PURE Swiss Opportunity REF (PSO) – successful completion of the significantly oversubscribed capital increase
PURE Swiss Opportunity REF (PSO) successfully completed a significantly oversubscribed CHF 40 Mio. capital increase, with 306,384 newly issued units and a total of 1,685,114 outstanding units
